Technical Analysis for RPHM - Reneo Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.64 -1.20% -0.02
RPHM closed down 1.2 percent on Monday, March 18, 2024, on 52 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Mar 25
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish -1.20%
Crossed Above 50 DMA Bullish -1.20%
Expansion Pivot Buy Setup Bullish Swing Setup -1.20%
Bollinger Band Squeeze Range Contraction -1.20%
BB Squeeze + Lower Band Touch Range Contraction -1.20%
BB Squeeze + Upper Band Touch Range Contraction -1.20%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 11 hours ago
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
50 DMA Support about 14 hours ago
Fell Below 20 DMA about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors

Is RPHM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.295
52 Week Low 0.9801
Average Volume 330,524
200-Day Moving Average 5.35
50-Day Moving Average 1.65
20-Day Moving Average 1.63
10-Day Moving Average 1.63
Average True Range 0.07
RSI (14) 44.75
ADX 15.63
+DI 17.10
-DI 15.78
Chandelier Exit (Long, 3 ATRs) 1.51
Chandelier Exit (Short, 3 ATRs) 1.76
Upper Bollinger Bands 1.67
Lower Bollinger Band 1.59
Percent B (%b) 0.62
BandWidth 4.59
MACD Line -0.04
MACD Signal Line -0.06
MACD Histogram 0.0181
Fundamentals Value
Market Cap 54.63 Million
Num Shares 33.3 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -0.69
Price-to-Sales 0.00
Price-to-Book 0.48
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.70
Resistance 3 (R3) 1.70 1.68 1.69
Resistance 2 (R2) 1.68 1.66 1.68 1.69
Resistance 1 (R1) 1.66 1.66 1.65 1.66 1.68
Pivot Point 1.64 1.64 1.64 1.64 1.64
Support 1 (S1) 1.62 1.62 1.61 1.62 1.60
Support 2 (S2) 1.60 1.62 1.60 1.59
Support 3 (S3) 1.58 1.60 1.59
Support 4 (S4) 1.58